Search results for "uva"

showing 10 items of 2916 documents

Multicentre propensity score-matched analysis of conventional versus extended abdominoperineal excision for low rectal cancer

2014

Abstract Background Abdominal perineal excision (APE) was originally described with levator ani removal for rectal cancer. An even wider, more aggressive extralevator resection for APE has been proposed. Although some surgeons are performing a very wide ‘extralevator APE (ELAPE)’, there are few data to recommend it routinely. This multicentre study aimed to compare outcomes of APE and ELAPE. Methods A multicentre propensity case-matched analysis comparing two surgical approaches (APE and ELAPE) was performed. All patients who underwent abdominoperineal resection of a rectal tumour were considered for the analysis. Tumour height was defined by magnetic resonance imaging measurement and patie…

MaleReoperationmedicine.medical_specialtymedicine.medical_treatmentPerforation (oil well)Anal CanalPerineumPostoperative ComplicationsmedicineHumansStage (cooking)Propensity ScoreNeoadjuvant therapyAgedRectal Neoplasmsbusiness.industryAbdominoperineal resectionPostoperative complicationMiddle AgedAnal canalTumor BurdenPerineumSurgerymedicine.anatomical_structureCase-Control StudiesPropensity score matchingFemaleSurgeryNeoplasm Recurrence LocalbusinessBritish Journal of Surgery
researchProduct

Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects

2013

Purpose: This post hoc analysis assessed switching to ezetimibe/simvastatin 10/20 mg vs doubling the baseline statin dose to simvastatin 40 mg or atorvastatin 20 mg or switching to rosuvastatin 10 mg in subgroups of obese (BMI ≥30 kg/m 2 ) and non-obese (BMI <30 kg/m 2 ) diabetic subjects. Methods: This was a randomized, double-blind, 12-week study of adults 18–79 years with cardiovascular disease with low-density lipoprotein cholesterol (LDL-C) ≥70 and ≤160 mg/dl. Percent change in LDL-C and other lipids was estimated. Results: In obese subjects (n = 466), percent changes in LDL-C and most other lipids were greater with ezetimibe/ simvastatin vs doubling the baseline statin dose or switchi…

MaleSimvastatinApolipoprotein BEndocrinology Diabetes and MetabolismAtorvastatinClinical Biochemistrychemistry.chemical_compoundEndocrinologyAtorvastatinRosuvastatin CalciumSulfonamidesNutrition and DieteticsbiologyAnticholesteremic AgentsDiabetesMiddle AgedRosuvastatin CalciumTreatment OutcomeFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtyStatinAdolescentmedicine.drug_classUrologyRosuvastatinYoung AdultEzetimibeDiabetes mellitusInternal medicineInternal MedicinemedicineHumansPyrrolesRosuvastatinObesitycardiovascular diseasesAgedApolipoproteins BBiochemistry medicalCholesterolbusiness.industryResearchBiochemistry (medical)Statinnutritional and metabolic diseasesCholesterol LDLEzetimibemedicine.diseasePeptide FragmentsFluorobenzenesDiabetes Mellitus Type 1PyrimidinesEndocrinologyDiabetes Mellitus Type 2chemistryHeptanoic AcidsSimvastatinbiology.proteinAzetidinesEzetimibe/simvastatinbusinessLipids in Health and Disease
researchProduct

A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in di…

2013

The low-density lipoprotein cholesterol (LDL-C) lowering efficacy of switching to ezetimibe/simvastatin (EZ/S) 10/20 mg versus doubling the run-in statin dose (to simvastatin 40 mg or atorvastatin 20 mg) or switching to rosuvastatin 10 mg in subjects with cardiovascular disease (CVD) and diabetes was assessed. Endpoints included percentage change in LDL-C and percentage of patients achieving LDL-C &lt;70 mg/dL. Significantly greater reductions in LDL-C occurred when switching to EZ/S versus statin doubling in the overall population and in subjects treated with simvastatin 20 mg or atorvastatin 10 mg (all p &lt; 0.001). The LDL-C reduction was numerically greater when switching to EZ/S vers…

MaleSimvastatinEndocrinology Diabetes and MetabolismAtorvastatinEzetimibe Simvastatin Drug CombinationPharmacologySeverity of Illness IndexAtorvastatinLongitudinal StudiesRosuvastatin CalciumAged 80 and overeducation.field_of_studySulfonamidesAnticholesteremic AgentsMiddle AgedRosuvastatin CalciumDrug CombinationsCardiovascular Diseaseslipids (amino acids peptides and proteins)FemaleDrug MonitoringCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyStatinmedicine.drug_classPopulationHypercholesterolemiaUrologyDiabetes ComplicationsEzetimibeDouble-Blind MethodInternal MedicinemedicineHumansRosuvastatinPyrrolescardiovascular diseaseseducationAgedbusiness.industrynutritional and metabolic diseasesCholesterol LDLFluorobenzenesPyrimidinesSimvastatinHeptanoic AcidsAzetidinesEzetimibe/simvastatinbusinessDiabetic AngiopathiesDiabetesvascular disease research
researchProduct

Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syn…

2011

Metabolic syndrome (MetS) is a clustering of atherosclerotic coronary heart disease risk factors. This post-hoc analysis compared the effects of switching to ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg in a cohort of 618 high-risk hypercholesterolaemic patients with ( n=368) and without ( n=217) MetS who had previously been on statin monotherapy. Patients were randomised 1:1 to double-blind ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg for 6 weeks. Least squares mean percent change from baseline and 95% confidence intervals in lipid efficacy parameters were calculated for the population and within subgroups. Treatment with ezetimibe/simvastatin was significantly more effect…

MaleSimvastatinSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismEzetimibe Simvastatin Drug CombinationCoronary DiseaseGastroenterologychemistry.chemical_compoundRisk FactorsDrug CombinationAzetidineAnticholesteremic AgentOdds RatioRosuvastatin CalciumMetabolic Syndromeeducation.field_of_studySulfonamidesDrug SubstitutionMetabolic Syndrome XAnticholesteremic AgentsLipidMiddle AgedLipidsEuropeRosuvastatin CalciumDrug CombinationsCholesterolTreatment Outcomelipids (amino acids peptides and proteins)FemaleCardiology and Cardiovascular Medicinemedicine.drugHumanmedicine.medical_specialtyStatinLogistic Modelmedicine.drug_classPopulationHypercholesterolemiaSulfonamideRisk AssessmentEzetimibeDouble-Blind MethodInternal medicineInternal MedicinemedicineHumansRosuvastatinLeast-Squares AnalysiseducationAgedApolipoproteins BLeast-Squares AnalysiAnalysis of VarianceCholesterolbusiness.industryRisk FactorFluorobenzenenutritional and metabolic diseasesCholesterol LDLFluorobenzenesEndocrinologyLogistic ModelsPyrimidineschemistryPyrimidineSimvastatinBiological MarkerAzetidinesEzetimibe/simvastatinHydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessBiomarkersDiabetesvascular disease research
researchProduct

Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and …

2011

OBJECTIVE: To evaluate relationships between apolipoprotein B (Apo B), LDL cholesterol (LDL-C), and non-HDL-C in high-risk patients treated with lipid-lowering therapy. DESIGN AND METHODS: This post-hoc analysis calculated LDL-C and non-HDL-C levels corresponding to an Apo B of 0.9 g/L following treatment with 1) statin monotherapy (baseline) and 2) ezetimibe/simvastatin 10/20mg or rosuvastatin 10mg (study end). The percentages of patients reaching LDL-C, non-HDL-C, and Apo B targets were calculated at study end. RESULTS: After switching to ezetimibe/simvastatin or rosuvastatin, the LDL-C and non-HDL-C corresponding to Apo B=0.9 g/L were closer to the more aggressive LDL-C and non-HDL-C goa…

MaleSimvastatinmedicine.medical_specialtySettore MED/09 - Medicina InternaStatinApolipoprotein Bmedicine.drug_classHypercholesterolemiaClinical BiochemistryCoronary DiseaseGastroenterologyRosuvastatinEzetimibeEzetimibe/simvastatin; Rosuvastatin; Correlation; Apolipoprotein B; Low-density lipoprotein cholesterol; Non-high-density lipoprotein cholesterolInternal medicinemedicineHumansLow-density lipoprotein cholesterolRosuvastatinRosuvastatin CalciumAgedApolipoproteins BLdl cholesterolSulfonamidesbiologyEzetimibe/simvastatinbusiness.industrynutritional and metabolic diseasesGeneral MedicineMiddle AgedEzetimibeCorrelationFluorobenzenesNon-high-density lipoprotein cholesterolCholesterolPyrimidinesSimvastatinNon hdl cholesterolbiology.proteinAzetidinesFemalelipids (amino acids peptides and proteins)Ezetimibe/simvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessApolipoprotein Bmedicine.drugClinical Biochemistry
researchProduct

Changes in the expression of cation-Cl- cotransporters, NKCC1 and KCC2, during cortical malformation induced by neonatal freeze-lesion.

2007

Focal cortical malformations comprise a heterogeneous group of disturbances in brain development, often associated with intractable epilepsy. A focal freeze-lesion of cerebral cortex in newborn rat produces a cortical malformation that resembles human polymicrogyria, clinical conditions that results from abnormal neuronal migration. The change in GABAergic functions that occurs during early brain development is induced by an alteration in Cl(-) homeostasis and plays important roles in neocortical development by modulating such events as laminar organization and synaptogenesis. We therefore investigated the relationship between pathogenesis of polymicrogyria and ontogeny of Cl(-) homeostasis…

MaleSodium-Potassium-Chloride SymportersSynaptogenesisDown-RegulationBiologyNervous System MalformationsLaminar organizationChloridesCell MovementChloride ChannelsCortex (anatomy)Parietal LobeGlial Fibrillary Acidic ProteinmedicinePolymicrogyriaAnimalsSolute Carrier Family 12 Member 2RNA MessengerRats Wistargamma-Aminobutyric AcidCerebral CortexSymportersGeneral NeuroscienceColocalizationCell DifferentiationGeneral Medicinemedicine.diseaseDenervationImmunohistochemistryMicrogyrusRatsUp-RegulationCold Temperaturemedicine.anatomical_structureNeuronal migration disorderBromodeoxyuridineCerebral cortexPhosphopyruvate HydrataseNeuroscienceBiomarkersNeuroscience research
researchProduct

Acute and overuse injuries among sports club members and non-members : the Finnish Health Promoting Sports Club (FHPSC) study

2018

Background Physical activity in adolescence is promoted for its multi-dimensional health benefits. However, too intensive sports participation is associated with an increased injury risk. Our aim was to compare the occurrence of acute and overuse injuries in Finnish sports club members and non-members and to report training and competing habits associated with a higher injury risk in sports club members. Methods In this cross-sectional survey targeted at 14–16-year-old adolescents, a structured questionnaire was completed by 1077 sports club members and 812 non-members. The main outcome measures were self-reported acute and overuse injuries, their location and type. Results At least one acu…

MaleSports club memberlcsh:Diseases of the musculoskeletal systemSports medicinemedicine.medical_treatmentnon-member0302 clinical medicineRisk FactorsSurveys and QuestionnairesEpidemiologyOrthopedics and Sports MedicineFinlandurheiluvammat030222 orthopedicsRehabilitationAcute DiseaseAthletic InjuriesFemaleCluburheiluseuratSportsResearch ArticleAcute injurymedicine.medical_specialtyOveruse injuryAdolescentCumulative Trauma DisorderseducationNon-memberHealth Promotion03 medical and health sciencesRheumatologyjäsenetInjury preventionmedicineHumansExercise030203 arthritis & rheumatologyAthletic injurybusiness.industryoveruse injurysports club memberOdds ratioacute injuryCross-Sectional Studiesathletic injuryadolescentOrthopedic surgeryAcute injuryPhysical therapylcsh:RC925-935businesshuman activities
researchProduct

Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national reg…

2021

Introduction: Preoperative treatment and adequate surgery increase local control in rectal cancer. However, modalities and indications for neoadjuvant treatment may be controversial. Aim of this study was to assess the trends of preoperative treatment and outcomes in patients with rectal cancer included in the Rectal Cancer Registry of the Spanish Associations of Surgeons. Method: This is a STROBE-compliant retrospective analysis of a prospective database. All patients operated on with curative intention included in the Rectal Cancer Registry were included. Analyses were performed to compare the use of neoadjuvant/adjuvant treatment in three timeframes: I)2006–2009; II)2010–2013; III)2014–2…

MaleSurvivalColorectal cancermedicine.medical_treatmentT stage030230 surgeryTNM0302 clinical medicineRegistriesStage (cooking)Rectal cancerAged 80 and overMargins of ExcisionGeneral MedicineMiddle AgedNeoadjuvant TherapySurvival Ratemedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleAdultmedicine.medical_specialtyNeoadjuvant treatmentPrognosiRectum03 medical and health sciencesYoung AdultmedicineAdjuvant therapyHumansChemotherapyAgedNeoplasm StagingRetrospective StudiesChemotherapyRadiotherapybusiness.industryRectal NeoplasmsCancerChemoradiotherapy Adjuvantmedicine.diseaseSurgeryRadiation therapySpainT-stageSurgerybusinessFollow-Up StudiesForecasting
researchProduct

Low doses of transdermal fentanyl in opioid-naive patients with cancer pain.

2010

The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) fentanyl patches in opioid-naive patients with cancer pain.This was a nonrandomized, open-label, uncontrolled study in fifty consecutive opioid-naive patients with advanced cancer and moderate pain. TD fentanyl was initiated at a dose of 12 µg/h. Doses were then adjusted according to the clinical response. Pain intensity, opioid-related adverse effects, TD fentanyl doses, and quality of life were monitored over 4 weeks. The time to dose stabilization and indexes of dose escalation were also calculated.Thirty-one patients completed all 4 weeks of the study. Pain control was achieved within a me…

MaleTransdermal patchCancer pain; Opioids; Trandermal fentanyl; Aged; Analgesia; Analgesics Opioid; Dose-Response Relationship Drug; Female; Fentanyl; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms; Pain; Palliative Care; Transdermal Patch; Medicine (all)medicine.medical_treatmentPainTransdermal PatchOpioidFentanylDose-Response RelationshipNeoplasmsmedicineHumansCancer painAdverse effectNeoadjuvant therapyTransdermalAgedAnalgesicsDose-Response Relationship Drugbusiness.industryMedicine (all)Palliative CareGeneral MedicineMiddle AgedNeoadjuvant TherapyOpioidsClinical trialAnalgesics OpioidFentanylTolerabilityTrandermal fentanylAnesthesiaFemaleDrugAnalgesiaCancer painbusinessmedicine.drugCurrent medical research and opinion
researchProduct

Outcomes of cataract surgery in diabetic patients: results of the Pan American Collaborative Retina Study Group.

2014

Purpose: This study was designed to evaluate the visual and anatomical outcomes after cataract surgery in diabetic patients with different intraoperative therapeutic strategies. Methods: The research design comprised of a multicentric, retrospective, interventional study conducted at 6 centers in Argentina, Brazil, Costa Rica, Puerto Rico, Spain, and Venezuela. We included 138 diabetic patients with at least 6-month follow-up following phacoemulsification and intraocular lens implantation. Best-corrected visual acuity (BCVA) and central subfield thickness were collected at baseline and at 1-, 2-, 3-, and 6-month follow-up. Of these, 42 cases were not treated with any intraoperative coadjuva…

MaleVascular Endothelial Growth Factor ATriamcinolone acetonideVisual acuitygenetic structuresmedicine.medical_treatmentExtração de catarataVisual AcuityIntraocular lensCuidados intraoperatóriosAngiogenesis InhibitorsTriamcinolonelcsh:OphthalmologyLens Implantation IntraocularDiabetic retinopathyAntibodies monoclonalAged 80 and overGeneral MedicineDiabetic retinopathyMiddle AgedMulticenter studyBevacizumabTreatment OutcomeCataract extractionChemotherapy AdjuvantEstudo multicêntricoIntravitreal InjectionsFemalemedicine.symptommedicine.drugAdultmedicine.medical_specialtyBevacizumabAntibodies Monoclonal HumanizedCataractMacular EdemaIntraoperative careOphthalmologyEdema macularmedicineAnticorpos monoclonaisHumansMacular edemaGlucocorticoidsAgedRetrospective StudiesMacular edemaDiabetic RetinopathyIntraoperative CarePhacoemulsificationbusiness.industryRetinopatia diabéticaPhacoemulsificationCataract surgeryFacoemulsificaçãomedicine.diseaseSurgeryImplante de lente intraocularOphthalmologyLens implantation intraocularlcsh:RE1-994businessFollow-Up StudiesArquivos brasileiros de oftalmologia
researchProduct